[Associations between candidate genes with schizophrenia susceptibility and the treatment efficiency].

AIM The aim of the study was to find genetic markers which can have influence on susceptibility of paranoid schizophrenia and the treatment efficiency measured by the PANSS (Positive and Negative Syndrome Scale). We analysed the gene polymorphisms: dopamine receptor--DRD2 (Taq 1A, in egzon 8,- 141 C ins/del), dopamine transporter--DAT, kainate receptor--GRIK3, serotonine transporter--SERT, serotonine receptor--5HT2A, mono amine oxidase A--MAO-A, catechol O-methyl transferase--COMT. METHOD One hundred four Polish patients with the diagnosis of paranoid schizophrenia were recruited as the study group. To obtain the diagnosis meeting the ICD-10 criteria, we used the Polish version of CIDI--Composite International Diagnostic Interview. Exclusion criteria included serious neurological disorders, major somatic disorders impairing cognitive functions and diagnosed mental impairment. The intensity of psychopathological symptoms was examined using the PANSS. Genomic DNA was extracted from leucocytes using the Miller's salting method. Polymorphisms were studied by the PCR (Polymerase Chain Reaction) method using RFLP (Restriction Fragments Length Polymorphism) and VNTR (Variable Number Tandem Repeat) technique. Statistical analyses were performed by the Statistica computer program, specifically Pearson's chi-square test. Associations between the treatment progress and the genotype were studied by analysis of variance (ANOVA). RESULTS We did not find associations between investigated gene polymorphisms and susceptibility of paranoid schizophrenia. Probably, there is no influence of studied polymorphisms on the treatment efficiency. CONCLUSIONS No differences were found in the genotypes distribution in the studied gene polymorphisms between the whole schizophrenics and the control group. No association was found between any particular genotype and the effect of antipsychotic treatment.

[1]  J. Hauser,et al.  [Lack of association between the insertion/deletion polymorphism in serotonin transporter gene, T102C polymorphism of the 5HT2A receptor gene and schizophrenia--family based study]. , 2010, Psychiatria polska.

[2]  J. Behravan,et al.  Linkage and association of DRD2 gene TaqI polymorphism with schizophrenia in an Iranian population. , 2008, Archives of Iranian medicine.

[3]  N. Woodward,et al.  COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia , 2007, Schizophrenia Research.

[4]  J. Hauser,et al.  [Lack of association between the insertion/deletion polymorphism in the serotonin transporter gene and schizophrenia]. , 2006, Psychiatria Polska.

[5]  J. Samochowiec,et al.  [Association of functional genes polymorphisms of key enzymes in the metabolism of biogenic amines with paranoid schizophrenia susceptibility and the influence of these polymorphisms on PANSS results in antipsychotic treatment]. , 2006, Psychiatria polska.

[6]  A. Malhotra,et al.  DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. , 2006, The American journal of psychiatry.

[7]  Lin He,et al.  Association study of serotonin 2A receptor (5-HT2A) gene with schizophrenia and suicidal behavior using systematic meta-analysis. , 2006, Biochemical and biophysical research communications.

[8]  Lin He,et al.  Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients , 2005, Neuroscience Letters.

[9]  S. Faraone,et al.  Meta-analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene , 2005, Schizophrenia Research.

[10]  Lin He,et al.  Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis , 2005, Biological Psychiatry.

[11]  M. Egan,et al.  Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications , 2004, Biological Psychiatry.

[12]  J Licinio,et al.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.

[13]  C. Pato,et al.  Family association study between DRD2 and DRD3 gene polymorphisms and schizophrenia in a Portuguese population , 2004, Psychiatry Research.

[14]  Chih-Chiang Chiu,et al.  Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. , 2002, The American journal of psychiatry.

[15]  G. Kirov,et al.  Schizophrenia and functional polymorphisms in the MAOA and COMT genes: no evidence for association or epistasis. , 2002, American journal of medical genetics.

[16]  J. Hauser,et al.  [Lack of association between VNTR polymorphism of DAT gene and schizophrenia]. , 2002, Psychiatria polska.

[17]  J. Hauser,et al.  [Lack of association between 141C Ins/Del promoter polymorphism of DRD2 gene and schizophrenia]. , 2002, Psychiatria Polska.

[18]  D. Rujescu,et al.  Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. , 2001, The American journal of psychiatry.

[19]  P. Gorwood,et al.  Association and excess of transmission of a DRD2 haplotype in a sample of French schizophrenic patients. , 2001, Schizophrenia Research.

[20]  T. Shinkai,et al.  Association analysis between two functional dopamine D2 receptor gene polymorphisms and schizophrenia. , 2001, American journal of medical genetics.

[21]  Joel B Greenhouse,et al.  Clinical Trials in Psychiatry , 2018, The Scope of Epidemiological Psychiatry.

[22]  D. Collier,et al.  Pharmacogenetic prediction of clozapine response , 2000, The Lancet.

[23]  D StClair,et al.  -141 C del/ins polymorphism of the dopamine receptor 2 gene is associated with schizophrenia in a British population. , 1999, American journal of medical genetics.

[24]  Yuhei Nakamura,et al.  Functional polymorphism of −141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia , 1998, Psychiatry Research.

[25]  D. Collier,et al.  Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia , 1998, Schizophrenia Research.

[26]  M. J. Arranz,et al.  Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response , 1998, Schizophrenia Research.

[27]  M. Passos-Bueno,et al.  Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brazilian patients affected by bipolar disorder and schizophrenia. , 1998, American journal of medical genetics.

[28]  T. Terao,et al.  Association study of a functional catechol-O-methyltransferase gene polymorphism in Japanese schizophrenics , 1998, Neuroscience Letters.

[29]  R. Murray,et al.  Catechol‐O‐methyltransferase polymorphisms and schizophrenia: a transmission disequilibrium study in multiply affected families , 1997, Psychiatric genetics.

[30]  W. Tsoi,et al.  Association between allele 1 of T102C polymorphism, 5-hydroxytryptamine 2a receptor gene and schizophrenia in Chinese males in Singapore. , 1997, Human heredity.

[31]  T. Arinami,et al.  A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. , 1997, Human molecular genetics.

[32]  M. Rietschel,et al.  Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: Identification of two naturally occurring receptor variants and association analysis in schizophrenia , 1996, Human Genetics.

[33]  P. McGuffin,et al.  No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). , 1995, American journal of medical genetics.

[34]  Tao Li,et al.  No association between alleles or genotypes at the dopamine transporter gene and schizophrenia , 1994, Psychiatry Research.

[35]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[36]  K. Mullis,et al.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. , 1985, Science.

[37]  P. Sharp,et al.  Physical mapping of temperature-sensitive mutations of adenoviruses. , 1975, Cold Spring Harbor symposia on quantitative biology.

[38]  M. Popoli,et al.  Association between the ionotropic glutamate receptor kainate 3 (GRIK3) ser310ala polymorphism and schizophrenia , 2002, Molecular Psychiatry.

[39]  E. Gershon,et al.  Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia , 2002, Molecular Psychiatry.

[40]  K. Lesch,et al.  Susceptibility for schizophrenia is not influenced by a functional insertion/deletion variant in the promoter of the serotonin transporter gene , 1998, European Archives of Psychiatry and Clinical Neuroscience.

[41]  R. Murray,et al.  Preferential transmission of the high activity allele of COMT in schizophrenia , 1996, Psychiatric genetics.

[42]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.